| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis (NCT07598825) | Amgen | 2026-09-07 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) (NCT06987539) | Amgen | 2026-08-31 |
| A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers (NCT07745907) | Amgen | 2026-08-07 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD (NCT07222553) | Amgen | 2026-07-31 |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) (NCT07684144) | Amgen | 2026-07-29 |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) (NCT07684235) | Amgen | 2026-07-23 |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) (NCT07700238) | Amgen | 2026-07-20 |
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia (NCT07223190) | Amgen | 2026-06-11 |
| A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus (NCT07590193) | Amgen | 2026-06-11 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration (NCT07614776) | Amgen | 2026-05-27 |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) (NCT07575399) | Amgen | 2026-05-11 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease (NCT07438405) | Amgen | 2026-05-07 |
| Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer (NCT07493512) | Amgen | 2026-04-28 |
| Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. (NCT07545226) | Amgen | 2026-04-21 |
| Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (NCT07531095) | Amgen | 2026-04-21 |
| Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy (NCT05909761) | Amgen | 2026-04-15 |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity (NCT07523711) | Amgen | 2026-04-09 |
| Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) (NCT07297979) | Amgen | 2026-04-08 |
| AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors (NCT07403721) | Amgen | 2026-04-08 |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial (NCT07293260) | Amgen | 2026-03-23 |
| Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta (NCT07366086) | Amgen | 2026-03-18 |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight (NCT07441252) | Amgen | 2026-03-05 |
| A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout (NCT07388498) | Amgen | 2026-02-09 |
| Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (NCT07422285) | Amgen | 2026-01-16 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation (NCT07172919) | Amgen | 2026-01-02 |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy (NCT07225686) | Amgen | 2025-12-19 |
| A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations (NCT07313761) | Amgen | 2025-12-15 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia (NCT07134088) | Amgen | 2025-12-08 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (NCT07213674) | Amgen | 2025-11-28 |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy (NCT07226765) | Amgen | 2025-11-25 |
| Effect of Maridebart Cafraglutide on the Heart's Electrical Activity (NCT07229157) | Amgen | 2025-10-22 |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations (NCT07226778) | Amgen | 2025-10-10 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer (NCT07140900) | Amgen | 2025-10-07 |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) (NCT07037758) | Amgen | 2025-09-16 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants (NCT07142642) | Amgen | 2025-08-26 |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events (NCT07136012) | Amgen | 2025-08-22 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (NCT07005128) | Amgen | 2025-08-18 |
| Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients (NCT07143513) | Amgen | 2025-08-11 |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors (NCT07094113) | Amgen | 2025-07-31 |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (NCT07037433) | Amgen | 2025-07-25 |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (NCT06570798) | Amgen | 2025-07-16 |
| Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients (NCT07085117) | Amgen | 2025-07-02 |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (NCT07037459) | Amgen | 2025-06-25 |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (NCT06987695) | Amgen | 2025-06-13 |
| A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China (NCT06588153) | Amgen | 2025-05-24 |
| Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (NCT06898957) | Amgen | 2025-05-16 |
| The Effect of AMG 133 on Gastric Emptying (NCT07429032) | Amgen | 2025-04-17 |
| Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants (NCT06910709) | Amgen | 2025-04-08 |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (NCT06858878) | Amgen | 2025-03-17 |
| A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function (NCT07428525) | Amgen | 2025-03-14 |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (NCT06858839) | Amgen | 2025-03-12 |
| A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body (NCT07429045) | Amgen | 2025-03-11 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (NCT06745323) | Amgen | 2025-02-26 |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) (NCT06747949) | Amgen | 2025-02-25 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (NCT06700343) | Amgen | 2025-01-13 |
| Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL) (NCT06649006) | Amgen | 2025-01-08 |
| A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) (NCT06593522) | Amgen | 2024-12-26 |
| A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity (NCT07310563) | Amgen | 2024-12-10 |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) (NCT06691984) | Amgen | 2024-12-09 |
| A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity (NCT07717814) | Amgen | 2024-11-26 |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer (NCT06613100) | Amgen | 2024-11-25 |
| A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss (NCT06761703) | Amgen | 2024-11-14 |
| A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) (NCT06660173) | Amgen | 2024-11-07 |
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. (NCT06321601) | Amgen | 2024-10-22 |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma (NCT06637371) | Amgen | 2024-10-16 |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (NCT06598306) | Amgen | 2024-10-07 |
| Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). (NCT06333951) | Amgen | 2024-09-17 |
| A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants (NCT06411860) | Amgen | 2024-09-12 |
| Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (NCT06430866) | Amgen | 2024-09-12 |
| Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity (NCT06585462) | Amgen | 2024-09-09 |
| Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (NCT06502977) | Amgen | 2024-08-27 |
| A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity (NCT06976372) | Amgen | 2024-08-20 |
| A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants (NCT06438263) | Amgen | 2024-08-06 |
| Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China (NCT06332014) | Amgen | 2024-08-06 |
| Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) (NCT06054113) | Amgen | 2024-07-23 |
| A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis (NCT06527404) | Amgen | 2024-07-18 |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (NCT06252649) | Amgen | 2024-07-17 |
| A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants (NCT06061523) | Amgen | 2024-07-15 |
| A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease (NCT06248619) | Amgen | 2024-07-05 |
| A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) (NCT06468826) | Amgen | 2024-06-18 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (NCT06211036) | Amgen | 2024-06-05 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease (NCT06401044) | Amgen | 2024-05-30 |
| A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) (NCT06360354) | Amgen | 2024-05-29 |
| A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma (NCT06376045) | Amgen | 2024-05-24 |
| A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (NCT06312020) | Amgen | 2024-05-09 |
| A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight (NCT06352892) | Amgen | 2024-04-25 |
| Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta (NCT05972551) | Amgen | 2024-04-22 |
| A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State (NCT06245408) | Amgen | 2024-04-08 |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT06180278) | Amgen | 2024-04-02 |
| A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis (NCT06224192) | Amgen | 2024-04-02 |
| A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout (NCT06229145) | Amgen | 2024-03-18 |
| A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT06131398) | Amgen | 2024-03-07 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (NCT06117774) | Amgen | 2024-02-20 |
| A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants (NCT06268860) | Amgen | 2024-02-15 |
| A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis (NCT06072482) | Amgen | 2024-02-07 |
| A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) (NCT05669014) | Amgen | 2023-12-04 |
| A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (NCT06122649) | Amgen | 2023-11-27 |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) (NCT05920356) | Amgen | 2023-11-16 |
| A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma (NCT06054555) | Amgen | 2023-11-02 |
| A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. (NCT06079476) | Amgen | 2023-10-30 |